Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Rheumatoid arthritis (RA) is a systemic inflammatory disease characterized by the destruction of joint tissues including cartilage and bone. Cartilage degradation is attributed to metalloproteinases (MPs) that belong to matrix metalloproteinase family and a disintegrin and metalloprotease with thrombospondin type 1 motifs produced by inflamed joint tissues. In addition, an enzyme that belongs to a disintegrin and metalloprotease family is also involved in release of inflammatory cytokines. Several highly selective inhibitors have been developed for MPs thought to play a role in RA pathogenesis and examining these inhibitors as potential drugs is becoming realistic. This chapter discusses recent reports on MPs in RA and their potential as a therapeutic target.

Original publication

DOI

10.1016/bs.pmbts.2017.03.002

Type

Chapter

Publication Date

2017

Volume

148

Pages

327 - 338

Keywords

ADAM, ADAMTS, Anti-TNF, Cartilage, Inflammation, MMPs, Metalloproteinases, Rheumatoid arthritis, Animals, Arthritis, Rheumatoid, Humans, Joints, Matrix Metalloproteinase Inhibitors, Matrix Metalloproteinases, Molecular Targeted Therapy